(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Lego's $650 Pokémon set is already sold out as demand, preorders surge - 2Wellness Bits of knowledge Readily available: A Survey of \Following Wellbeing and Progress\ Wellness Wearables
- 3Ancient mass grave discovered in water cistern during Tel Azekah excavations
- 47 Strange Apparatuses to Make Your Party Stick Out!
- 5Grasping the Basics of Business Land Regulation
- UK, Canada, Germany, others condemn Israel's West Bank settlement plan
- Germany expresses 'great concern' over Israel's new death penalty law
- Progress Over Perfection: Lessons From Garment Factories Fighting Heat Stress
- NASA's giant moon rocket, in photos
- 5 Different ways Macintosh is Prepared to Overwhelm Gaming, Even Against Windows
- Collins Foods to offload 20 Taco Bell outlets in Australia
- NASA’s Artemis II launch leaves Americans in awe: ‘We’re going to the frickin’ moon!’
- 5 Cell phones of the Year
- 2 ways you can conserve the water used to make your food
